ANI Pharma plans Delaware Supreme Court appeal in CG Oncology dispute

ANI Pharmaceuticals, Inc.
CG Oncology, Inc.

ANI Pharmaceuticals, Inc.

ANIP

0.00

CG Oncology, Inc.

CGON

0.00
  • ANI Pharmaceuticals will appeal to the Delaware Supreme Court after a trial judge denied its post-trial motions in a dispute with CG Oncology.
  • The company sought a new trial plus judgment as a matter of law on an unjust enrichment claim tied to assets sold to CG Oncology in 2010.
  • ANI is pursuing recovery of the assets’ value, including a claimed 5% running royalty on future worldwide sales of cretostimogene grenadenorepvec.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607161634PRIMZONEFULLFEED9763690) on July 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.